August 7, 2025 — Leads & Copy — NEW YORK — Soligenix Inc. (NASDAQ: SNGX) has been featured in an editorial by NetworkNewsWire (NNW), part of the Dynamic Brand Portfolio@IBN, which focuses on financial news distribution.
The article, titled “Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,” discusses the increasing healthcare challenges posed by chronic and rare diseases, especially among older adults.
Soligenix is advancing its HyBryte(TM) platform as a therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting older adults. The company has established U.S.-based manufacturing for HyBryte’s active ingredient, supporting domestic innovation for this patient group.
Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs. Their pipeline includes HyBryte(TM) for CTCL, synthetic hypericin (“SGX302”) for psoriasis, dusquetide (“SGX942”) for inflammatory diseases, and vaccine programs for ricin toxin, filoviruses, and COVID-19.
Contact:
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
Source: Soligenix Inc.
